Below are the most recent publications written about "Lymphoproliferative Disorders" by people in Profiles.
-
Massicotte-Azarniouch D, Detwiler RK, Hu Y, Falk RJ, Saha MK, Hogan SL, Derebail VK. Malignancy risk in kidney transplant recipients exposed to immunosuppression pre-transplant for the treatment of glomerulonephritis. Nephrol Dial Transplant. 2023 08 31; 38(9):2009-2018.
-
Plumptre IR, Said JT, Sun T, Larocca C, Virgen CA, Kupper TS, Fisher DC, Devlin PM, Elco CP, Song JS, LeBoeuf NR. Clinical features and treatment outcomes for primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: a retrospective cohort study from the Dana-Farber Cancer Institute and updated literature review. Leuk Lymphoma. 2022 12; 63(12):2832-2846.
-
Plumptre IR, Said JT, Sheu Song J, Corey K, LeBoeuf NR. Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder in children: A case report and review of the literature. Pediatr Blood Cancer. 2022 09; 69(9):e29862.
-
Ahmadi E, Ravanshad M, Xie J, Panigrahi R, Jubbal SS, Guru SK, Guangping G, Ziyaeyan M, Fingeroth J. Serotype-dependent recombinant adeno-associated vector (AAV) infection of Epstein-Barr virus-positive B-cells, towards recombinant AAV-based therapy of focal EBV?+?lymphoproliferative disorders. Virol J. 2021 11 18; 18(1):223.
-
Sanikommu SR, Reese ES, He J, Lee C, Ai J, Butler CM, Jacobs R, Hu B, Atrash S, Trivedi J, Bhutani M, Voorhees P, Usmani SZ, Ghosh N, Fasan O, Druhan LJ, Symanowski J, Copelan EA, Avalos BR. Cost saving, patient centered algorithm for progenitor cell mobilization for autologous hematopoietic cell transplantation. J Clin Apher. 2021 Aug; 36(4):553-562.
-
Brar N, Butzmann A, Kumar J, Peerani R, Morgan EA, Grigoriadis G, Kumar B, Tatarczuch RM, Warnke RA, Ohgami RS. LIM domain only 2 (LMO2) expression distinguishes T-lymphoblastic leukemia/lymphoma from indolent T-lymphoblastic proliferations. Histopathology. 2020 Dec; 77(6):984-988.
-
Naik S, Riches M, Hari P, Kim S, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, Chhabra S, Daly A, Storek J, Ustun C, Diaz MA, Cerny J, Beitinjaneh A, Yared J, Brown V, Page K, Dahi PB, Ganguly S, Seo S, Chao N, Freytes CO, Saad A, Savani BN, Woo Ahn K, Boeckh M, Heslop HE, Lazarus HM, Auletta JJ, Kamble RT. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. Transpl Infect Dis. 2019 Oct; 21(5):e13145.
-
Garc?a-Cadenas I, Y??ez L, Jarque I, Martino R, P?rez-Sim?n JA, Valc?rcel D, Sanz J, Berm?dez A, Mu?oz C, Calder?n-Cabrera C, Garc?a E, Alonso L, Su?rez-Lled? M, Gonz?lez Vicent M, Heras I, Viguria MC, Batlle M, V?zquez L, L?pez J, Solano C. Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH). Eur J Haematol. 2019 Jun; 102(6):465-471.
-
Xia D, Morgan EA, Berger D, Pinkus GS, Ferry JA, Zukerberg LR. NK-Cell Enteropathy and Similar Indolent Lymphoproliferative Disorders: A Case Series With Literature Review. Am J Clin Pathol. 2019 01 01; 151(1):75-85.
-
Dugan JP, Haverkos BM, Villagomez L, Martin LK, Lustberg M, Patton J, Martin M, Huang Y, Nuovo G, Yan F, Cavaliere R, Fingeroth J, Kenney SC, Ambinder RF, Lozanski G, Porcu P, Caligiuri MA, Baiocchi RA. Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone. Clin Cancer Res. 2018 07 15; 24(14):3273-3281.